SCHEMBL1090631

SCHEMBL1090631

CN(C)c1ccc(CN2CC(Nc3nccc(N4CCCCCC4)n3)C2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.65
ALDH1A1 P00352 3/20 0.48
HRH4 Q9H3N8 6/20 0.47
ROCK2 O75116 1/20 0.42
KAT2B Q92831 1/20 0.41
USP2 O75604 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
MRGPRX1 Q96LB2 1/20 0.39
ACHE P22303 1/20 0.39
BACE1 P56817 1/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1089356 0.93 CXCR4 (0.76) CXCR4ALDH1A1HRH4ROCK2KAT2B
SCHEMBL1088899 0.92 CXCR4 (0.69) CXCR4ALDH1A1HRH4ROCK2KAT2B
SCHEMBL1088802 0.91 CXCR4 (0.67) CXCR4ALDH1A1HRH4ACHEBACE1
SCHEMBL1089449 0.91 CXCR4 (0.64) CXCR4ALDH1A1HRH4HRH3MRGPRX1
SCHEMBL1090768 0.88 CXCR4 (0.69) CXCR4HRH4ROCK2HRH3MRGPRX1
SCHEMBL1090422 0.86 CXCR4 (0.69) CXCR4HRH4ROCK2HRH3MRGPRX1
SCHEMBL1090654 0.86 CXCR4 (0.69) CXCR4HRH4HRH3MRGPRX1ACHE
SCHEMBL1089573 0.86 CXCR4 (0.85) CXCR4HRH4HRH3ACHEBACE1
SCHEMBL1090388 0.86 CXCR4 (0.71) CXCR4HRH4ROCK2CYP1A2CYP3A4
SCHEMBL1090222 0.85 CXCR4 (0.65) CXCR4HRH4ROCK2HRH3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885ALDH1A1 916/4885HRH4 130/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885ALDH1A1 916/4885HRH4 130/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885ALDH1A1 916/4885HRH4 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.